Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni with a vision of enabling regenerative medicine to become reality. Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials. For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process. Source
No articles found.
Assertio Therapeutics is committed to providing responsible solutions to advance p...
Assertio Therapeutics is committed to providing...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
Chembio is a leading point-of-care diagnostics company focused on detecting and di...
Chembio is a leading point-of-care diagnostics ...
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...
Organogenesis Holdings Inc. is a leading regene...
Join the National Investor Network and get the latest information with your interests in mind.